+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Spinal Muscular Atrophy Treatment Market by Treatment Type (Gene Therapy, SMN2-Targeted Therapy, Supportive Therapy), Disease Type (Type 1, Type 2, Type 3), End User - Global Forecast 2025-2030- Product Image
Spinal Muscular Atrophy Treatment Market by Treatment Type (Gene Therapy, SMN2-Targeted Therapy, Supportive Therapy), Disease Type (Type 1, Type 2, Type 3), End User - Global Forecast 2025-2030- Product Image
Sale

Spinal Muscular Atrophy Treatment Market by Treatment Type (Gene Therapy, SMN2-Targeted Therapy, Supportive Therapy), Disease Type (Type 1, Type 2, Type 3), End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012079
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Spinal Muscular Atrophy Treatment Market is evolving rapidly, shaped by breakthrough therapies and heightened global focus on improving patient outcomes. Senior decision-makers require actionable, evidence-based insights to navigate this sophisticated landscape and anticipate the factors influencing growth and access.

Market Snapshot: Spinal Muscular Atrophy Treatment Market Overview

The Spinal Muscular Atrophy Treatment Market grew from USD 1.85 billion in 2024 to USD 2.15 billion in 2025. The market is expected to expand at a CAGR of 15.44%, reaching USD 4.38 billion by 2030. Growth is driven by rapid advances in gene therapies, supportive interventions, and favorable regulatory momentum. Rising investment in rare neuromuscular disorders and increased collaboration among biotechnology innovators are contributing to improved treatment access and furthering innovation across multiple care settings.

Scope & Segmentation of the Market

  • Treatment Types: Gene therapy, SMN2-targeted therapy, and supportive therapy each address distinctive disease stages and clinical needs.
  • Disease Types: Segmentation includes Type 1, Type 2, Type 3, and Type 4 Spinal Muscular Atrophy, reflecting varying degrees of severity and treatment pathways.
  • End Users: Hospitals, homecare settings, and specialty clinics are vital channels for therapy delivery, each with unique operational challenges and patient care demands.
  • Regions Covered: Americas (including the United States, Canada, Mexico, Brazil, and Argentina), Europe, Middle East & Africa (with key markets such as Germany, France, and the United Kingdom), and Asia-Pacific (including China, India, Japan, Australia, and others).
  • Key Companies: Biogen Inc., Novartis AG, Roche Holding AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., Biohaven, Ltd., NMD PHARMA A/S, Cytokinetics, Genzyme Corporation among others.

Key Takeaways for Decision-Makers

  • Gene therapy has established a new standard for disease-modifying interventions, resulting in revised benchmarks for clinical benefit and durability across SMA subtypes.
  • Cooperative frameworks between pharmaceutical companies and biotechnology start-ups have accelerated research and streamlined manufacturing transitions, positively impacting therapy availability.
  • Stakeholder engagement, led by patient advocacy groups, has become central to clinical development, ensuring that evolving treatment options align with real-world patient needs.
  • Care delivery across diverse settings, including home and outpatient clinics, demands robust logistics and support infrastructure to optimize outcomes and enhance patient quality of life.
  • Regulatory agility and payer collaboration now play crucial roles in establishing tailored reimbursement models and enabling access to innovative therapies.
  • Regional policy differences continue to shape commercialization, requiring companies to customize strategies based on local healthcare structures and reimbursement practices.

Tariff Impact Analysis

Forthcoming United States tariff policies set for 2025 are projected to increase costs for key raw materials and bioprocessing equipment within the Spinal Muscular Atrophy Treatment Market. Manufacturers may reconsider supply chain configurations, potentially relocating production or renegotiating supplier contracts. While these adjustments could strengthen resilience, smaller biotechnology firms may experience increased pressures that delay clinical programs. Collaborative procurement and long-term alliances are being explored to lessen negative cost and access implications.

Methodology & Data Sources

This report integrates comprehensive primary research involving interviews with clinicians, regulatory experts, and patient advocates. Secondary research covers peer-reviewed journals, regulatory documentation, and public reports. Analytical methods include scenario modeling and stakeholder validation to assure balanced, actionable insights.

Why This Report Matters

  • Enables informed strategy by synthesizing current therapeutic, policy, and economic trends across key market segments.
  • Guides investment and operational planning through deep regional and segmentation analysis, reflecting both innovation and market-access challenges.
  • Supports executive decision-making by providing a validated roadmap for product development, commercialization, and stakeholder alignment.

Conclusion

The Spinal Muscular Atrophy Treatment Market stands at a critical juncture, shaped by scientific, commercial, and policy transformations. This report equips leaders with the frameworks and insight required to drive sustainable market success and advance patient-centric care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advances in next-generation gene therapy delivery methods for spinal muscular atrophy
5.2. Emerging oral small-molecule splicing modulators improving treatment accessibility in SMA patients
5.3. Real-world effectiveness and long-term safety data fostering payer reimbursement decisions for SMA therapies
5.4. Development of combination therapies targeting SMN-independent pathways to enhance neuroprotective outcomes in SMA
5.5. Expansion of newborn screening initiatives enabling presymptomatic treatment and improved survival rates in SMA
5.6. Impact of upcoming biosimilar launches on pricing dynamics and market access for nusinersen in global SMA markets
5.7. Integration of telehealth and digital monitoring platforms to optimize long-term management of spinal muscular atrophy
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Spinal Muscular Atrophy Treatment Market, by Treatment Type
8.1. Introduction
8.2. Gene Therapy
8.3. SMN2-Targeted Therapy
8.4. Supportive Therapy
9. Spinal Muscular Atrophy Treatment Market, by Disease Type
9.1. Introduction
9.2. Type 1
9.3. Type 2
9.4. Type 3
9.5. Type 4
10. Spinal Muscular Atrophy Treatment Market, by End User
10.1. Introduction
10.2. Homecare Settings
10.3. Hospitals
10.4. Specialty Clinics
11. Americas Spinal Muscular Atrophy Treatment Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Spinal Muscular Atrophy Treatment Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Spinal Muscular Atrophy Treatment Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Biogen Inc.
14.3.2. Novartis AG
14.3.3. Roche Holding AG
14.3.4. Ionis Pharmaceuticals, Inc.
14.3.5. PTC Therapeutics, Inc.
14.3.6. Biohaven, Ltd.
14.3.7. NMD PHARMA A/S
14.3.8. Cytokinetics
14.3.9. Biohaven, Ltd.
14.3.10. Genzyme Corporation
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. SPINAL MUSCULAR ATROPHY TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 12. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 14. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 20. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 21. SPINAL MUSCULAR ATROPHY TREATMENT MARKET: RESEARCHAI
FIGURE 22. SPINAL MUSCULAR ATROPHY TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 23. SPINAL MUSCULAR ATROPHY TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 24. SPINAL MUSCULAR ATROPHY TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMN2-TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMN2-TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 36. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 37. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 38. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 39. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 40. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 41. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 42. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 43. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 44. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 45. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 46. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 47. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 50. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 51. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 52. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 53. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 54. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 55. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 56. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 57. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 58. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 59. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 60. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 61. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 64. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 65. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 66. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 67. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 70. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 71. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 72. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 73. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 84. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 86. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 90. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 91. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 92. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 93. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 96. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 97. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 98. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 99. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 102. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 103. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 104. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 105. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 108. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 109. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 110. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 111. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 114. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 115. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 116. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 117. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 120. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 121. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 122. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 123. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 126. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 127. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 128. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 132. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 133. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 134. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 135. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 138. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 139. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 140. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 141. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 144. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 145. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 146. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 147. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 150. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 151. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 152. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 153. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 156. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 157. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 158. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 159. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 162. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 163. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 164. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 165. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 168. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 169. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 170. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 171. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 174. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 175. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 176. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 177. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 180. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 181. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 182. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 183. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 186. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 187. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 188. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 189. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 192. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 193. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 194. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 195. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 198. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 199. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 200. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 201. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 204. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 205. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 206. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 207. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 210. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 212. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 216. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 217. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 218. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 219. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 220. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 221. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 224. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 225. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 226. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 227. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 230. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 231. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 232. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 233. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 236. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 237. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 238. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 239. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 242. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 243. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 244. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 245. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 248. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 249. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 250. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 251. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 254. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 255. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 256. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 257. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 260. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 261. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 262. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 263. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 266. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 267. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 268. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 269. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 272. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 273. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 274. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 275. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 278. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 279. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 280. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 281. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 284. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 285. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 286. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 287. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
TABLE 290. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

  • Biogen Inc.
  • Novartis AG
  • Roche Holding AG
  • Ionis Pharmaceuticals, Inc.
  • PTC Therapeutics, Inc.
  • Biohaven, Ltd.
  • NMD PHARMA A/S
  • Cytokinetics
  • Biohaven, Ltd.
  • Genzyme Corporation

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.15 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.38 Billion
Compound Annual Growth Rate15.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Drugs for Spinal Muscular Atrophy Market by Product Type (Antisense Oligonucleotide, Gene Therapy, Small Molecule), Treatment Type (Combination Therapy, Monotherapy), Distribution Channel, Patient Age Group - Global Forecast 2025-2030 - Product Image

Drugs for Spinal Muscular Atrophy Market by Product Type (Antisense Oligonucleotide, Gene Therapy, Small Molecule), Treatment Type (Combination Therapy, Monotherapy), Distribution Channel, Patient Age Group - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Spinal Muscular Atrophy Treatment Global Market Report 2025 - Product Image

Spinal Muscular Atrophy Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment, By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment, By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Spinal Muscular Atrophy Treatment Market Report and Forecast 2025-2034 - Product Image

Spinal Muscular Atrophy Treatment Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Spinal Muscular Atrophy Market Report 2025 - Product Image

Spinal Muscular Atrophy Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Spinal Muscular Atrophy Drug Market

Spinal Muscular Atrophy (SMA) is a rare genetic disorder that affects the motor neurons in the spinal cord, leading to progressive muscle weakness and wasting. As a result, individuals with SMA experience difficulty with activities of daily living, such as walking, eating, and breathing. Treatment for SMA is focused on managing symptoms and slowing the progression of the disease. The SMA drug market is a subset of the Central Nervous System (CNS) drug market. CNS drugs are used to treat a variety of neurological disorders, including SMA. Currently, there are several drugs approved for the treatment of SMA, including Spinraza, Zolgensma, and Evrysdi. These drugs are designed to slow the progression of the disease and improve the quality of life for those affected. Some of the companies in the SMA drug market include Biogen, Novartis, AveXis, and Roche. These companies are actively researching and developing new treatments for SMA, as well as providing access to existing treatments. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.